IMBDX 메인으로

기본 H1

기본 H2

기본 H3

핵심기술

보이지 않는 암을 빠르고 정확하게 발견할 수 있습니다.

발표

Clinical validation of WES-based HRD scoring and its prognostic value for PARP inhibitor maintenance therapy in ovarian cancer

2026-05-15

Abstract

Background:
Homologous recombination deficiency (HRD) is an important biomarker for predicting response to PARP inhibitor (PARPi) therapy in ovarian cancer. This study evaluated the clinical performance and prognostic value of a whole-exome sequencing (WES)-based HRD assay.

 

Methods:
Eighty-one ovarian cancer patients treated with PARPi therapy were analyzed using the CancerProfiler™ WES panel. HRD scores were calculated based on genomic scar signatures, while germline and somatic BRCA1/2 mutations were simultaneously assessed. The prognostic impact of HRD status and BRCA mutations on progression-free survival (PFS) was evaluated.

 

Results:
HRD-high status (≥50) was strongly associated with improved PARPi treatment outcomes, particularly in treatment-naïve tumors. HRD-high patients showed significantly longer progression-free survival compared with HRD-low patients in both first- and second-line settings. In contrast, BRCA mutation status demonstrated more limited and treatment-dependent predictive value. HRD-high status remained an independent predictor of favorable outcomes after recurrence.

 

Conclusions:
WES-based HRD scoring is a robust predictor of PARPi benefit in ovarian cancer and may provide broader clinical utility than BRCA mutation status alone. These findings support further validation of WES-based HRD assays as scalable alternatives for precision oncology.

 

Citation:
DongSoo Kyung et al. “Clinical validation of WES-based HRD scoring and its prognostic value for PARP inhibitor maintenance therapy in ovarian cancer.” Presented at the American Association for Cancer Research Annual Meeting 2026, April 17–22, 2026, San Diego, CA. Published in Cancer Research 2026;86(7 Suppl): Abstract 4019.